The earnings call presents a positive outlook with significant progress in clinical trials, especially with the initiation of the VERSATILE 003 Phase 3 trial and promising Phase 2 results. Financial metrics show improvement, but operational costs and cash flow remain challenges.

Company Guidance -

Q2 2025

In the first quarter of 2025, PDS Biotech reported a net loss of approximately $8.5 million, translating to $0.21 per basic and diluted share, compared to $10.6 million or $0.30 per share in the same period of 2024. This improvement was primarily driven by increased tax benefits and reduced operating expenses, with research and development costs decreasing from $6.7 million to $5.8 million, and general administrative expenses slightly decreasing to $3.3 million. Total operating expenses were $9.1 million, down from $10.1 million the previous year. The company ended the quarter with a cash balance of $40 million, down from $41.7 million at the end of 2024. Additionally, PDS Biotech successfully raised $11 million through a securities purchase agreement and completed a debt refinancing to extend the term by 36 months, with the first four months being interest-only.

Initiation of VERSATILE 003 Phase 3 Trial

PDS Biotech initiated the VERSATILE 003 Phase 3 clinical trial for Versamune HPV plus pembrolizumab, targeting HPV16-positive head and neck cancer. The trial design has been approved by the FDA and includes 350 patients.

Positive Phase 2 VERSATILE 002 Results

The VERSATILE 002 trial showed encouraging patient survival and clinical responses, with a median overall survival of 30 months compared to the standard 12 months for HPV16-positive head and neck cancer.

FDA IND Clearance for New Drug

FDA cleared the investigational new drug application for Versamune MUC1 and IL-12 fused antibody drug conjugate PDS01ADC for metastatic colorectal cancer.

Strong Financial Position

Reported a net loss of $8.5 million, an improvement from the previous year's $10.6 million. Cash balance stood at $40 million as of March 31, 2025.

PDS Biotechnology (PDSB) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

PDSB Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 13, 2025	2025 (Q2)	-0.23 / -	-0.23	―	―	―
May 14, 2025	2025 (Q1)	-0.25 / -0.21	-0.3	30.00% (+0.09)	―
Mar 27, 2025	2024 (Q4)	-0.28 / -0.21	-0.35	40.00% (+0.14)	―
Nov 14, 2024	2024 (Q3)	-0.30 / -0.29	-0.35	17.14% (+0.06)	―
Aug 13, 2024	2024 (Q2)	-0.33 / -0.23	-0.37	37.84% (+0.14)	―	―
May 15, 2024	2024 (Q1)	-0.37 / -0.30	-0.32	6.25% (+0.02)	―	―
Mar 27, 2024	2023 (Q4)	-0.44 / -0.35	-0.65	46.15% (+0.30)	―
Nov 14, 2023	2023 (Q3)	-0.45 / -0.35	-0.26	-34.62% (-0.09)	―
Aug 14, 2023	2023 (Q2)	-0.35 / -0.37	-0.2	-85.00% (-0.17)	―
May 15, 2023	2023 (Q1)	-0.30 / -0.32	-0.32	0.00% (0.00)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

PDSB Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 14, 2025	$1.27	$1.31	+3.15%
Mar 27, 2025	$1.24	$1.25	+0.81%
Nov 14, 2024	$2.76	$2.25	-18.48%
Aug 13, 2024	$3.05	$3.05	0.00%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does PDS Biotechnology Corporation (PDSB) report earnings?

PDS Biotechnology Corporation (PDSB) is schdueled to report earning on Aug 13, 2025, TBA (Confirmed).

What is PDS Biotechnology Corporation (PDSB) earnings time?

PDS Biotechnology Corporation (PDSB) earnings time is at Aug 13, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is PDSB EPS forecast?

PDSB EPS forecast for the fiscal quarter 2025 (Q2) is -0.23.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing